top of page

Head of RSPAD Visits Dexa Group Facilities, Supports the Use of OMAI Phytopharmaceuticals for National Health Independence

  • Writer: Corry Saputra
    Corry Saputra
  • Mar 26, 2024
  • 2 min read

Updated: Jan 14



Dexa Group welcomed the visit of the Head of the Gatot Soebroto Central Army Hospital (Rumah Sakit Pusat Angkatan Darat (RSPAD)), Lieutenant General (Lt. Gen.) Dr. Albertus Budi Sulistya, along with his delegation, to the Dexa Laboratories of Biomolecular Sciences (DLBS) in Cikarang, West Java, on Tuesday, March 26, 2024. During the visit, it was highlighted that Dexa Group consistently supports national health independence, mainly by developing Indonesian Indigenous Modern Medicines (Obat Modern Asli Indonesia (OMAI)).


"We feel a renewed sense of spirit here, inspired by the vision of Dexa Medica's founder, Mr. Rudy Soetikno. Dexa has always emphasized nationalism, which is deeply inspiring, including the extraordinary roadmap for OMAI development we learned about today," said Lt. Gen. Budi.


Lt. Gen. Budi was accompanied by key personnel, including RSPAD Expert Doctor in Cellcure, Dr. Dwi Edi Wahono; Head of Education and Training under the Director of Development & Research, Drs. Latif Usman; Head of the Indonesian Army CellsCure Center (IA2C), Dr. Martina Lily Yana; Hospital Management System Expert, Dr. Timbul Partogi Haposan Simorangkir; Head of Clinical Pathology Installation, Dr. Yudi Susanto; and Head of Research and Development, Ms. Yanti, among others. From Dexa Group, attendees included Dexa Group Leader Mr. Ferry Soetikno, DLBS Executive Director Prof. Raymond Tjandrawinata, Corporate Affairs Director Mr. Tarcisius Tanto Randy, and Dexa Medica Sales Director Mr. Marimin.


Mr. Ferry Soetikno shared that Dexa Group has been conducting research and development on OMAI since 2005 through DLBS. "Today, we aim to share what Dexa has achieved, the research we have undertaken, the results we have produced, and the challenges we face to discuss actionable steps going forward," he explained.


Prof. Raymond added that DLBS was established to fulfill the vision of Dexa Group's founder, the late Lt. Col. (Ret.) Rudy Soetikno, Apt., to ensure OMAI products are accessible to all Indonesians, including private, public, and military hospitals.


He emphasized that OMAI is developed using advanced technology, certified by Good Manufacturing Practices (CPOB), and is high-quality, reliable, and halal. In addition to being available domestically, OMAI is also widely exported to international markets.


"We must become leaders in our country, realizing Mr. Rudy Soetikno's vision. We cannot lose to imported herbal products. We must create opportunities for OMAI to be respected in its home country," Prof. Raymond stated.


During the event, Dexa Medica Sales Director Mr. Marimin expressed his gratitude for the collaboration and support from the Indonesian Army in advancing health independence in Indonesia.


"As the central hospital of the Indonesian Army and a teaching hospital, RSPAD is expected to inspire other military hospitals nationwide with the spirit of independence. We hope that OMAI phytopharmaceuticals can become a treatment option at RSPAD," said Mr. Marimin.



bottom of page